Form 4: EXAGEN Director Paul Kim Granted 9,000 Stock Options, Aligning Interests with Shareholders

EXAGEN Inc. Director Paul Kim was granted 9,000 stock options with an exercise price of $7.36, increasing his total beneficial ownership of derivative securities to 18,000.

Summary

• Paul Kim, a Director of EXAGEN INC. (XGN), was granted 9,000 stock options on June 10, 2025.
• Each option has an exercise price of $7.36 per share.
• The options will vest and become exercisable on the first anniversary of the grant date (June 10, 2026) or the next occurring annual meeting of the Issuer's stockholders, whichever comes first, contingent on Mr. Kim's continued service on the board.
• The options are set to expire on June 9, 2035.
• Following this transaction, Mr. Kim beneficially owns a total of 18,000 derivative securities (stock options) in EXAGEN INC.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options to a director is a standard practice that aligns management's interests with shareholders, indicating stable corporate governance and a commitment to long-term value creation.

Positives

• The grant of stock options to Director Paul Kim aligns his personal financial interests with those of the company's shareholders, as the options gain value only if the stock price increases above the exercise price.
• This is a standard practice for director compensation, indicating continuity in corporate governance and compensation policies.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

The grant of stock options to directors is a common practice across various industries, particularly in biotechnology and healthcare, to incentivize long-term commitment and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a widely accepted practice, comparable to compensation structures seen in other publicly traded companies, especially those in the life sciences sector like Myriad Genetics, Inc. (MYGN) or Veracyte, Inc. (VCYT), where equity incentives are common for board members.

Related Party Transactions

• The grant of 9,000 stock options to Paul Kim, a Director of EXAGEN INC., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The option grant aligns the director's incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The granted stock options will vest on the first anniversary of the grant date or the next annual meeting, subject to continued service.
• Paul Kim may choose to exercise these options at any point after vesting and before their expiration date.

Key Dates

Keywords

EXAGEN, XGN, Paul Kim, stock option, director compensation, insider transaction, Form 4, beneficial ownership, equity compensation